{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-043064","form_type":"8-K","ticker":"BDSX","cik":"0001439725","company_name":"BIODESIX INC","filed_at":"2021-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.120472+00:00","generated_at":"2026-06-29T16:31:21.293279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"confidence":"high","headline":"Biodesix Q2 total revenue $11.9M (+180%), core lung diagnostics $4.8M (+109%); NGS test launch accelerated to Q1 2022","bullets":["Total revenue $11.9M (+180% YoY); core lung diagnostic revenue $4.8M (+109%).","COVID-19 testing revenue $6.1M (+345%) but declining sequentially; net loss $11.4M (+38%).","Gross profit $4.8M (40% margin); operating expenses $15.4M (+93%) due to sales force buildout.","Nodify XL2 milestone triggers $37M obligation payable over six quarterly installments starting Jan 2022.","Accelerated launch of 72-hour liquid NGS test to Q1 2022; cash $56.3M; expects $3.1M PPP loan forgiveness."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-043064","json":"https://secwatch.observer/filing/0001564590-21-043064.json","markdown":"https://secwatch.observer/filing/0001564590-21-043064.md","text":"https://secwatch.observer/filing/0001564590-21-043064.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439725/000156459021043064/0001564590-21-043064-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439725/000156459021043064/bdsx-8k_20210810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T16:31:21.293279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}